223 related articles for article (PubMed ID: 21986138)
1. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma.
Yuan XK; Zhao XK; Xia YC; Zhu X; Xiao P
J Int Med Res; 2011; 39(4):1381-91. PubMed ID: 21986138
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
3. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
Huang H; Zhang G; Li G; Ma H; Zhang X
Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
[TBL] [Abstract][Full Text] [Related]
4. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Toyoda M; Takahashi K; Yamamoto T; Masuyama K
Cancer Sci; 2012 Jun; 103(6):976-83. PubMed ID: 22360618
[TBL] [Abstract][Full Text] [Related]
6. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
Raychaudhuri B; Rayman P; Ireland J; Ko J; Rini B; Borden EC; Garcia J; Vogelbaum MA; Finke J
Neuro Oncol; 2011 Jun; 13(6):591-9. PubMed ID: 21636707
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
9. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
Filipazzi P; Valenti R; Huber V; Pilla L; Canese P; Iero M; Castelli C; Mariani L; Parmiani G; Rivoltini L
J Clin Oncol; 2007 Jun; 25(18):2546-53. PubMed ID: 17577033
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
11. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
12. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
[TBL] [Abstract][Full Text] [Related]
13. The study of CD14+HLA-DR-/low myeloid-drived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function.
Du J; Sun X; Song Y
Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):62-67. PubMed ID: 28466815
[TBL] [Abstract][Full Text] [Related]
14. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
15. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
[TBL] [Abstract][Full Text] [Related]
16. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
Lin Y; Gustafson MP; Bulur PA; Gastineau DA; Witzig TE; Dietz AB
Blood; 2011 Jan; 117(3):872-81. PubMed ID: 21063024
[TBL] [Abstract][Full Text] [Related]
18. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
[TBL] [Abstract][Full Text] [Related]
20. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Cancer Res; 2013 Jul; 73(13):3877-87. PubMed ID: 23633486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
